The gastrointestinal molecular diagnostics company’s facility adds College of American Pathologists accreditation to its existing CLIA certification.
Cyted Health, a gastrointestinal molecular diagnostics company, announced its US laboratory has achieved accreditation from the College of American Pathologists (CAP).
The accreditation builds on the laboratory’s Clinical Laboratory Improvement Amendments (CLIA) certification, which was obtained in January 2024. CAP accreditation is widely recognized as an industry benchmark for pathology and laboratory medicine, confirming operational measures, technical proficiency, and standards of quality assurance and control.
“Achieving CAP accreditation reflects Cyted Health’s commitment to the highest standards in laboratory practice, recognizing our dedication to excellence and precision in detecting esophageal diseases earlier,” says Betsy Hanna, president and US general manager at Cyted Health, in a release.
The accreditation, paired with the existing CLIA certification regulated by the Centers for Medicare & Medicaid Services, confirms that the laboratory practices meet industry standards, according to the company.
Cyted Health is currently conducting the DETECT-ME clinical validation study, which has been enrolling patients across multiple sites in the US since March 2025. This study is designed to validate the clinical performance of the company’s newest molecular tests for the detection of esophageal conditions using EndoSign.
The company’s platform combines minimally invasive cell collection with high-resolution molecular analysis to detect early biological changes associated with Barrett’s esophagus and cancer. To date, Cyted Health has conducted more than 40,000 tests using its diagnostic platform.
ID 219558869 | Accredited © Cagkan Sayin | Dreamstime.com
